138 related articles for article (PubMed ID: 37793854)
21. Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.
Iyengar P; Wardak Z; Gerber DE; Tumati V; Ahn C; Hughes RS; Dowell JE; Cheedella N; Nedzi L; Westover KD; Pulipparacharuvil S; Choy H; Timmerman RD
JAMA Oncol; 2018 Jan; 4(1):e173501. PubMed ID: 28973074
[TBL] [Abstract][Full Text] [Related]
22. Clinical Outcomes of Stereotactic Ablative Radiotherapy for All Stages of Non-Small Cell Lung Cancer; Definitive versus Consolidative.
Kim H; Kim SM; Yang DS; Lee KH; Kim YB
Medicina (Kaunas); 2022 Sep; 58(9):. PubMed ID: 36143981
[No Abstract] [Full Text] [Related]
23. SUVmax Predicts Disease Progression after Stereotactic Ablative Radiotherapy in Stage I Non-small Cell Lung Cancer.
Kwak YK; Park HH; Choi KH; Park EY; Sung SY; Lee SW; Hong JH; Lee HC; Yoo IR; Kim YS
Cancer Res Treat; 2020 Jan; 52(1):85-97. PubMed ID: 31122008
[TBL] [Abstract][Full Text] [Related]
24. A competing risk analysis of the patterns and risk factors of recurrence in early-stage non-small cell lung cancer treated with stereotactic ablative radiotherapy.
Tonneau M; Richard C; Routy B; Campeau MP; Vu T; Filion E; Roberge D; Mathieu D; Doucet R; Beliveau-Nadeau D; Bahig H
Radiother Oncol; 2023 Aug; 185():109697. PubMed ID: 37169303
[TBL] [Abstract][Full Text] [Related]
25. Prognostic factors in medically inoperable early stage lung cancer patients treated with stereotactic ablative radiation therapy (SABR): Turkish Radiation Oncology Society Multicentric Study.
Sahin B; Atalar B; Kaytan Saglam E; Akgun Z; Abacioglu U; Arifoglu A; Ozyar E; Yaprak G; Ozseker Isik N; Guney Y; Caglar HB; Karaman S; Igdem S; Selek U; Berber T; Oner Dincbas F; Sengoz M; Yucel S; Demiral AN; Akyurek S
Clin Respir J; 2020 Nov; 14(11):1050-1059. PubMed ID: 32749053
[TBL] [Abstract][Full Text] [Related]
26. Stereotactic radiotherapy (SABR) for the treatment of primary non-small cell lung cancer; systematic review and comparison with a surgical cohort.
Soldà F; Lodge M; Ashley S; Whitington A; Goldstraw P; Brada M
Radiother Oncol; 2013 Oct; 109(1):1-7. PubMed ID: 24128806
[TBL] [Abstract][Full Text] [Related]
27. Definitive Management of Presumed Synchronous Early Stage Non-Small Cell Lung Cancers: Outcomes and Utility of Stereotactic Ablative Radiation Therapy.
Ayoub Z; Ning MS; Brooks ED; Kang J; Welsh JW; Chen A; Gandhi S; Heymach JV; Vaporciyan AA; Chang JY
Int J Radiat Oncol Biol Phys; 2020 Jun; 107(2):261-269. PubMed ID: 32044413
[TBL] [Abstract][Full Text] [Related]
28. Pulmonary function and quality of life after VMAT-based stereotactic ablative radiotherapy for early stage inoperable NSCLC: a prospective study.
Ferrero C; Badellino S; Filippi AR; Focaraccio L; Giaj Levra M; Levis M; Moretto F; Torchio R; Ricardi U; Novello S
Lung Cancer; 2015 Sep; 89(3):350-6. PubMed ID: 26164208
[TBL] [Abstract][Full Text] [Related]
29. Is radiofrequency ablation more effective than stereotactic ablative radiotherapy in patients with early stage medically inoperable non-small cell lung cancer?
Bilal H; Mahmood S; Rajashanker B; Shah R
Interact Cardiovasc Thorac Surg; 2012 Aug; 15(2):258-65. PubMed ID: 22581864
[TBL] [Abstract][Full Text] [Related]
30. Stereotactic Body Radiotherapy Is Effective in Modifying the Tumor Genome and Tumor Immune Microenvironment in Non-Small Cell Lung Cancer or Lung Metastatic Carcinoma.
Zhou P; Chen D; Zhu B; Chen W; Xie Q; Wang Y; Tan Q; Yuan B; Zuo X; Huang C; Zhu H; Li G
Front Immunol; 2020; 11():594212. PubMed ID: 33552051
[TBL] [Abstract][Full Text] [Related]
31. Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis.
Snyder A; Nathanson T; Funt SA; Ahuja A; Buros Novik J; Hellmann MD; Chang E; Aksoy BA; Al-Ahmadie H; Yusko E; Vignali M; Benzeno S; Boyd M; Moran M; Iyer G; Robins HS; Mardis ER; Merghoub T; Hammerbacher J; Rosenberg JE; Bajorin DF
PLoS Med; 2017 May; 14(5):e1002309. PubMed ID: 28552987
[TBL] [Abstract][Full Text] [Related]
32. Stereotactic Ablative Body Radiotherapy Versus Radical Radiotherapy: Comparing Real-World Outcomes in Stage I Lung Cancer.
Phillips I; Sandhu S; Lüchtenborg M; Harden S
Clin Oncol (R Coll Radiol); 2019 Oct; 31(10):681-687. PubMed ID: 31377081
[TBL] [Abstract][Full Text] [Related]
33. Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer.
Chang JY; Liu H; Balter P; Komaki R; Liao Z; Welsh J; Mehran RJ; Roth JA; Swisher SG
Radiat Oncol; 2012 Sep; 7():152. PubMed ID: 22963661
[TBL] [Abstract][Full Text] [Related]
34. Assessment of tumour response after stereotactic ablative radiation therapy for lung cancer: A prospective quantitative hybrid
Yang DM; Palma D; Louie A; Malthaner R; Fortin D; Rodrigues G; Yaremko B; Laba J; Gaede S; Warner A; Inculet R; Lee TY
J Med Imaging Radiat Oncol; 2019 Feb; 63(1):94-101. PubMed ID: 30281918
[TBL] [Abstract][Full Text] [Related]
35. Short report: interim safety results for a phase II trial measuring the integration of stereotactic ablative radiotherapy (SABR) plus surgery for early stage non-small cell lung cancer (MISSILE-NSCLC).
Palma DA; Nguyen TK; Kwan K; Gaede S; Landis M; Malthaner R; Fortin D; Louie AV; Frechette E; Rodrigues GB; Yaremko B; Yu E; Dar AR; Lee TY; Gratton A; Warner A; Ward A; Inculet R
Radiat Oncol; 2017 Jan; 12(1):30. PubMed ID: 28129789
[TBL] [Abstract][Full Text] [Related]
36. Stereotactic ablative radiotherapy before resection to avoid delay for early-stage lung cancer or oligometastases during the COVID-19 pandemic: Pathologic outcomes from the SABR-BRIDGE protocol.
Kidane B; Gerard IJ; Spicer J; Kim JO; Fiset PO; Wawryko P; Cecchini MJ; Inculet R; Abdulkarim B; Fortin D; Qiabi M; Qing G; Enns S; Bashir B; Tankel J; Wakeam E; Warner A; Kopek N; Yaremko BP; Rodrigues GB; Laba JM; Qu M; Malthaner RA; Palma DA
Cancer; 2023 Sep; 129(18):2798-2807. PubMed ID: 37221679
[TBL] [Abstract][Full Text] [Related]
37. Is stereotactic ablative radiotherapy equivalent to sublobar resection in high-risk surgical patients with stage I non-small-cell lung cancer?
Mahmood S; Bilal H; Faivre-Finn C; Shah R
Interact Cardiovasc Thorac Surg; 2013 Nov; 17(5):845-53. PubMed ID: 23900381
[TBL] [Abstract][Full Text] [Related]
38. Application of real-time MRI-guided linear accelerator in stereotactic ablative body radiotherapy for non-small cell lung cancer: one step forward to precise targeting.
Kang HJ; Kwak YK; Kim M; Lee SJ
J Cancer Res Clin Oncol; 2022 Nov; 148(11):3215-3223. PubMed ID: 36040666
[TBL] [Abstract][Full Text] [Related]
39. Endoscopic nodal staging in oligometastatic non-small cell lung cancer (NSCLC) being treated with stereotactic ablative radiotherapy (ENDO-SABR).
Dhaliwal I; Kassirian S; Mitchell MA; Qiabi M; Warner A; Louie AV; Wong HH; McDonald CM; Rajchgot J; Palma DA
BMC Cancer; 2022 Apr; 22(1):468. PubMed ID: 35484614
[TBL] [Abstract][Full Text] [Related]
40. Forecasting the impact of stereotactic ablative radiotherapy for early-stage lung cancer on the thoracic surgery workforce.
Edwards JP; Datta I; Hunt JD; Stefan K; Ball CG; Dixon E; Grondin SC
Eur J Cardiothorac Surg; 2016 Jun; 49(6):1599-606. PubMed ID: 26796110
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
